CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells

被引:44
作者
Beyersdorf, N
Hanke, T
Kerkau, T
Hünig, T
机构
[1] Univ Wurzburg, Inst Virol & Immunbiol, D-97078 Wurzburg, Germany
[2] TeGenero ImmunoTherapeut AG, Wurzburg, Germany
关键词
CD28; superagonists; regulatory T cells (T-reg cells); autoimmunity;
D O I
10.1016/j.autrev.2005.06.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There is strong evidence that a quantitative and/or functional deficiency in CD4(+)CD25(+) regulatory T cells (T-reg cells) plays a key role in the pathogenesis of many human autoimmune diseases. Therefore, targeting regulatory T cells with novel forms of immunotherapy should provide a means for successfully battling autoimmunity in humans. We have recently shown that superagonistic monoclonal antibodies with specificity for CD28 (CD28 superagonists) are capable of activating and preferentially expanding T-reg cells over conventional T cells in vitro and, importantly, also in vivo. Moreover, therapeutic application of CD28 superagonists elicited profound therapeutic effects in various animal models of autoimmunity, including experimental autoimmune encephalomyelitis (EAE) and adjuvant arthritis (AA) of the Lewis rat. Adoptive transfer experiments with T-reg cells from CD28 superagonist-treated rats proved that protection from EAE is, indeed, mediated by CD28 superagonist-activated T-reg cells. Therefore, effective targeting of CD4+CD25+ regulatory T cells makes CD28 superagonists a promising novel tool for the treatment of human autoimmune diseases. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:40 / 45
页数:6
相关论文
共 33 条
[21]   Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self [J].
Sakaguchi, S .
NATURE IMMUNOLOGY, 2005, 6 (04) :345-352
[22]  
SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
[23]   B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes [J].
Salomon, B ;
Lenschow, DJ ;
Rhee, L ;
Ashourian, N ;
Singh, B ;
Sharpe, A ;
Bluestone, JA .
IMMUNITY, 2000, 12 (04) :431-440
[24]   Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies [J].
Schmidt, J ;
Elflein, K ;
Stienekemeier, M ;
Rodriguez-Palmero, M ;
Schneider, C ;
Toyka, KV ;
Gold, R ;
Hünig, T .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 140 (1-2) :143-152
[25]   Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization [J].
Setoguchi, R ;
Hori, S ;
Takahashi, T ;
Sakaguchi, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (05) :723-735
[26]   CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28 [J].
Tacke, M ;
Hanke, G ;
Hanke, T ;
Hunig, T .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (01) :239-247
[27]   CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2 [J].
Tai, XG ;
Cowan, M ;
Feigenbaum, L ;
Singer, A .
NATURE IMMUNOLOGY, 2005, 6 (02) :152-162
[28]   In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes [J].
Tang, QZ ;
Henriksen, KJ ;
Bi, MY ;
Finger, EB ;
Szot, G ;
Ye, JQ ;
Masteller, EL ;
McDevitt, H ;
Bonyhadi, M ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (11) :1455-1465
[29]   Cutting edge:: CD28 controls peripheral homeostasis of CD4+CD25+ [J].
Tang, QZ ;
Henriksen, KJ ;
Boden, EK ;
Tooley, AJ ;
Ye, JQ ;
Subudhi, SK ;
Zheng, XX ;
Strom, TB ;
Bluestone, JA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (07) :3348-3352
[30]   CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes [J].
Tarbell, KV ;
Yamazaki, S ;
Olson, K ;
Toy, P ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (11) :1467-1477